David Moore has been Senior Vice President, Commercial, since August
2017 and joined Novo Nordisk, Inc. as Senior Vice President of
Marketing in May 2017. He serves as the principal leader for Novo
Nordisk's US sales and marketing teams across its diabetes and obesity
portfolios. His responsibilities include oversight of commercial
operations including sales, brand strategies and initiatives to
enhance the company's growth and presence in the United States.
Mr. Moore has more than 20 years of sales, marketing and executive management experience, including extensive US and global brand management leadership in multiple therapeutic areas including metabolic and cardiovascular, specialty and rare diseases.
Prior to joining Novo Nordisk, Mr. Moore served as President and Chief Commercial Officer of Cempra Pharmaceuticals, a publicly traded biotech company. Mr. Moore started his career in 1997 at Johnson & Johnson (J&J) Ortho-McNeil Pharmaceutical in sales and sales management and then moved into a director role in market access. He spent extensive time in J&J product marketing and new product development, last serving as Group Marketing Director for the Janssen Pharmaceutical Pain Franchise. In 2013, he left J&J to join Tranzyme Pharma as Executive Vice President, Global Commercial Operations and Chief Business Officer. When Tranzyme merged with Ocera Therapeutics, Mr. Moore was appointed Chief Business Officer and successfully led the integration prior to joining Cempra.
Mr. Moore is a part-time faculty member at Duke FUQUA School of Business and Duke Integrative Medicines. He holds an MBA in marketing from Lehigh University and a bachelor's degree in biology from Towson University.